Of note, in both of the tumour samples from this patient the observed prevalence of the AKT3 E17K mutation was ∼30% (Figure 1A), meaning that ∼60% of the analysed cells harbour the mutation if it is heterozygous. This evidence concerns the gene AKT3 and neoplasm.